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Abstract
Background: The common response to stopping anti-HIV treatment is an increase of HIV-RNA
load and decrease in CD4+, but not all the patients have similar responses to this therapeutic
strategy. The aim was to identify predictive markers of CD4+ cell count declines to < 350/µL in
CD4-guided antiretroviral treatment interruptions.
Methods: 27 HIV-infected patients participated in a prospective multicenter study in with a 24
month follow-up. Patients on stable highly active antiretroviral therapy (HAART), with CD4+ count
> 600/µL, and HIV-RNA < 50 copies/ml for at least 6 months were offered the option to
discontinue antiretroviral therapy. The main outcome was a decline in CD4+ cell count to < 350/µL.
Results: After 24 months of follow-up, 16 of 27 (59%) patients (who discontinued therapy)
experienced declines in CD4+ cell count to < 350/µL. Patients with a CD4+ nadir of < 200 cells/µL
had a greater risk of restarting therapy during the follow-up (RR (CI95%): 3.37 (1.07; 10.36)).
Interestingly, lymphoproliferative responses to Mycobacterium tuberculosis purified protein
derivative (PPD) below 10000 c.p.m. at baseline (4.77 (1.07; 21.12)), IL-4 production above 100 pg/
mL at baseline (5.95 (1.76; 20.07)) in PBMC cultured with PPD, and increased IL-4 production of
PBMC with p24 antigen at baseline (1.25 (1.01; 1.55)) were associated to declines in CD4+ cell
count to < 350/µL.
Conclusion:  Both the number (CD4+  nadir) and the functional activity of CD4+
(lymphoproliferative response to PPD) predict the CD4+ decrease associated with discontinuation
of ART in patients with controlled viremia.
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Background
After more than ten years of use, combination antiretrovi-
ral therapy (ART) continues to have a significant impact
on the morbidity and mortality of HIV infection [1,2].
Despite significant improvement in the toxicity profile
and the convenience of administration of currently rec-
ommended therapies, the need for lifelong ART makes it
desirable to find ways of decreasing the exposure to drugs
[3]. Treatment interruption has been proposed as one
such a possibility and it has been explored in several clin-
ical studies in different contexts [4-6].
Recently, large clinical trials have concluded that treat-
ment interruptions can no longer be recommended due to
the risk of clinical progression in some circumstances [4].
However, other studies, both retrospective and prospec-
tive, carried out under different conditions, have reached
different conclusions [5,6]. In these studies, patients who
discontinue therapy are not at an increased risk of clinical
progression provided that ART is reinitiated before CD4+
counts fall below 200 cells/mm3. These studies have uni-
formly identified the nadir CD4+ count or the CD4+ count
at the time of initiation of ART as the single, most impor-
tant predictive marker of the duration of treatment inter-
ruption [4-6]. No other host factors have been identified
so far, and in particular, there is no data on the relevance
of the functional activity of CD4+ T-cells in the decrease of
CD4+ counts in persons who discontinue successful ART.
The aim of this study was to identify predictive markers
for declines in CD4+ cell count to < 350/µL and to evaluate
the long-term effects of CD4-guided antiretroviral treat-
ment interruptions (TI).
Methods
Population and study design
A prospective study of the immune, viral, and clinical out-
comes of ART interruptions in 27 patients with chroni-
cally suppressed HIV-1 infection was carried out in four
Spanish hospitals to evaluate the long-term effects of ART
interruptions. In addition to the main results of the study,
we report herein the factors that have been identified as
predictors of the likelihood of a CD4+ count decrease after
a follow-up of 24 months, in these 27 patients.
The decision to interrupt ART was made jointly by the
physician and the patient, during two weeks, while an
offer to be included in this study was made to all the HIV
patient from several different hospitals. 27 patients
responded affirmatively and a written informed consent
form was obtained from all patients. The Ethics Commit-
tee of the participating hospitals approved the study.
Inclusion criteria for HIV-infected patients on highly
active antiretroviral therapy (HAART) interruption were
age > 18 years, stable HAART, CD4+ > 600/µL, and HIV-
RNA load < 50 copies/ml for at least 6 months before dis-
continuing therapy. Patients were excluded if they previ-
ously had AIDS, ART failure, or poor adherence to HAART
(< 90%), or if they were pregnant or had been splenect-
omized. Patients were evaluated monthly during the first
three months and every two months thereafter. The crite-
ria for reintroducing HAART, if needed, were: (i) patient's
choice, at any CD4+ count level; (ii) appearance of symp-
toms that could be manifestations of HIV infection (CDC
category B events and/or AIDS defining events); and (iii)
a decreasing CD4+ count before falling below 350 cells/
µL. We checked clinical parameters and measured T-cell
subsets, HIV-RNA load, and lymphoproliferative
responses (LPR) to different stimuli in vitro.
T-cell subsets and HIV-RNA viral load
T lymphocyte CD4 cell counts were determined in whole
blood by flow cytometry (FACScan, Becton-Dickinson
Immunocytometry Systems, San Jose, CA, USA). Plasma
HIV-1 RNA was quantified using the Amplicor Ultransen-
sitive Assay (Roche Amplicor HIV-1 Monitor assay, ver-
sion 1.5) with a limit of detection of 50 copies/mL.
Lymphocyte proliferative assays
Peripheral blood mononuclear cells (PBMC) were seeded
in 96-well flat-bottom microtiter plates (2 × 105/200µl per
well) resuspended in RPMI-1640 medium supplemented
with 10% fetal calf serum. The cells were stimulated with
several stimuli (p24 HIV-1 antigen (p24-Ag), streptoki-
nase (SK), tetanus toxoid (TT), Mycobacterium tuberculosis
purified protein derivative (PPD), and pokeweed). Cul-
tures were made as reported previously [7]. The cells were
harvested in glass fiber filters with an automatic cell har-
vester and radioactive incorporation was measured with a
liquid scintillation spectrometer. Assays were carried out
in quadruplicate and the results were expressed as "c.p.m.
net": LPR of stimulated PBMC was corrected by subtract-
ing the values of unstimulated PBMC.
Multiplex cytokine analysis
Multiplex suspension bead array immunoassay was per-
formed using the Luminex 100™ analyzer (Luminex Cor-
poration, Austin, TX, USA) to identify protein expression
in culture supernatants according to the manufacturers'
specifications. Multiplex kit (LINCOplex™; LINCO
Research, St. Charles, MO 63304, USA) was used to spe-
cifically evaluate IL-4 and INF-γ. A minimum of 100
events (beads) was collected for each of the analyte pro-
tein and median fluorescence intensities (MFI) were
obtained. Analyte protein concentrations were automati-
cally calculated based on standard curve data using Mas-
terPlex™ QT Analysis version 2 (MiraiBio, Inc., Alameda,
CA). A five-parameter regression formula was used to cal-
culate the sample concentrations from the standard
curves.BMC Infectious Diseases 2008, 8:20 http://www.biomedcentral.com/1471-2334/8/20
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Statistical analysis
All p-values were 2-tailed, and the threshold of signifi-
cance was set at 0.05. All statistical analyses were per-
formed with SPSS 12.0 software (SPSS INC, Chicago, IL,
USA).
The outcome variables examined were analyzed by the
Kaplan-Meier method. This was considered as the dura-
tion between the baseline timepoint (HAART interrup-
tion) and the appearance of a decrease in CD4+ (values of
CD4+ < 350/µL, CD4+ < 400/µL, and CD4+ < 500/µL) and
an increase of VL (values of VL > 10,000 copies/mL and VL
> 30,000 copies/mL).
The value of immunological characteristics to predict
declines in CD4+ cell counts to < 350/µL in HIV-infected
patients after treatment interruption was analyzed by Cox
regression Immunologic characteristics (predictive mark-
ers) as a continuous and dichotomic variable. We did not
make a multivariate analysis due to the low number of
patients included in this study.
Results
Table 1 shows the demographic, immunological and viro-
logical characteristics of the 27 HIV-infected patients who
were included in the study. During follow up, one patient
developed an acute retroviral syndrome and two patients
presented thrombocytopenia (< 50,000 platelet/mm3) for
which they had to restart HAART (with CD4+ > 350 cell/
µL). The rest of patients remained completely asympto-
matic and did not show signs of clinical progression.
Evolution of immunological and virological markers
Figure 1A shows the proportion of HIV-1-infected patients
who experienced a decrease in CD4+ 24 months after treat-
ment interruption. A decrease in the CD4+ count was
observed in all the patients, 23 (85%) patients experi-
enced declines in CD4+ cell count to < 500/µL, 19 (70%)
in CD4+ to < 400/µL, and 16 (59%) in CD4+ to < 350/µL.
The patients who experienced declines in CD4+ cell count
< 350/µL restarted HAART. Figure 1B shows details on the
proportion of HIV-1-infected patients who experienced an
increase in VL during follow-up. An increase in the VL was
observed in all the patients. Twenty two (81%) patients
had VL > 30,000 copies/mL and 13 (48%) patients had VL
> 100,000 copies/mL. Interestingly, the patients with high
HIV-RNA load when starting HAART had a high likeli-
hood to achieve a HIV-RNA load rebound of both >
30,000 copies/mL (RR: 1.85 per log10; CI95%: 1.02; 3.35;
p = 0.04) and > 100,000 copies/mL (2.45; 1.12; 5.36; p =
0.02) after ART interruption.
Immunologic characteristics to predict declines in CD4+ 
cell count < 350/µL
The analysis of characteristics shown in Table 2 concluded
that the CD4+ nadir, the CD4+ count at of initiation of
HAART, and the CD4+ at study entry (at baseline) were all
predictive of declines in CD4+ cell count to < 350/µL dur-
ing ART interruption in the period of study. We looked for
functional characteristics of CD4+ T cells that could be
associated with the decline of CD4+ count after ART dis-
continuation. Interestingly, lymphoproliferative
responses to PPD at baseline was inversely related to a
decline in CD4+ cell count to < 350/µL during follow-up
after ART interruption (Table 2). Patients with a LPR to
PPD < 10,000 c.p.m. net at baseline had a relative risk
(RR) of about 4.7 to experience a decline in CD4+ cell
count to < 350/µL. The analysis of LPRs to other stimuli
(p24-Ag, SK, and TT) did not reveal any significant associ-
ation.
Similarly, IL-4 production in supernatant of PBMC cul-
tured with PPD at baseline was also associated with an
increased risk of experiencing a decline in CD4+ cell count
to < 350/µL during ART interruption (Table 2). Patients
with IL-4 production > 100 pg/mL in supernatant of
PBMC cultured with PPD at baseline had a RR of about 6
to experience a CD4+ cell count decline to < 350/µL, and
IL-4 production in supernatant of cultured PBMC with
p24-Ag at baseline had a RR of about 1.2 to experience the
same decline (Table 2).
Table 1: Clinical, immunological and virological parameters of 27 
HIV-1-infected patients who discontinued antiretroviral 
therapy.
Characteristic Values
N2 7
Males 19 (70%)
Age in years 36.7 ± 1.09 (27; 52)
HCV coinfection 6 (22%)
HIV transmission category
Intravenous drug user 4 (15%)
Homosexual 11 (41%)
Heterosexual 12 (44%)
Duration of HIV-infection in years 6.9 ± 0.6 (2; 14)
Symptomatic HIV disease, non AIDS 4 (16%)
Time on HAART in months 46.6 ± 3.1 (20.7; 95.1)
HIV-RNA, log10 copies/mL 4.2 ± 0.2 (2.3; 5.6)
Maximal HIV-RNA 4.4 ± 0.2 (2.7; 6.2)
Time with HIV-RNA < 50 inmonths 29.3 ± 2.3 (6; 56.2)
CD4+ T-cell count/µL
CD4+ T-cell at HAART initiation 504 ± 50 (50; 1150)
% CD4+ T-cell at HAART initiation 25.2 ± 1.4 (13; 38)
CD4+ T-cell nadir 440 ± 42 (50; 1113)
CD4+ T-cell at study entry, baseline 959 ± 55 (611; 1973)
C%D4+ T-cell at study entry, baseline 39.1 ± 1.5 (28; 56)
CD4+ T-cell increase on HAART 486 ± 60 (116; 1397)
%CD4+ T-cell increase on HAART 14.6 ± 1.5 (0; 22)
Values are expressed as mean ± standard error mean (min.; max.) and 
absolute count.BMC Infectious Diseases 2008, 8:20 http://www.biomedcentral.com/1471-2334/8/20
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Discussion
This study confirms the importance of the CD4+ count
before initiation of antiretroviral therapy as a predictor of
the need to reassume therapy during the 24 months fol-
lowing interruption of ART [8,9]. Not surprisingly, we
have found that other immunological factors are predic-
tors of the CD4+decrease after treatment interruption. Not
only the number (CD4+ nadir count) but also the function
(lymphoproliferative response to some antigens) of the
immune system seem to be important predictors of the
CD4+ decrease associated to discontinuation of ART in
well controlled subjects.
As to be expected from previous reports, patients in this
study experienced rebounds in HIV-RNA load to pre-
HAART levels during TI [10]. Moreover, no immunologi-
cal markers were associated with an increase of HIV-RNA
load. We only found that the HIV-RNA load upon starting
HAART had a positive association with HIV-RNA load
rebounds of > 30,000 copies/mL and > 100,000 copies/
mL.
HIV-1 infection is characterized by persistent viremia and
a progressive decline in both the number and function of
CD4+ T cells, including the decrease of LPR to mitogens
and antigens [11] and the lack of an effective HIV-1-spe-
cific immune response [12]. It is also clear that some
patients have a greater impairment of the immune system
than others during the course of HIV infection. HAART
may cause the recovery of pathogen-specific immune
responses in a majority of subjects, but HIV-specific
immunity remains largely ineffective and most people
with chronic HIV infection cannot control viremia after
interruption of HAART [8,13]. In our study we found that
the patients had a decrease in CD4+ and increase of more
than 4 log10 of HIV-RNA load during follow-up.
LPR  in vitro is a good test to measure the quality of
immune response. LPR to PPD is a marker of cellular
immune damage, and its loss is associated with immuno-
deficiency [14]. The patients with a low LPR to PPD at
baseline had a higher risk of their CD4+ falling below 350/
µL. This may be a consequence of prior severe immune
damage leading to the loss of antigen-specific memory T
cells [15]. So, LPR to PPD adds important quality infor-
mation with regard to reaching low CD4+ count in HIV-
infected patients during ART interruption. Our results
indicate that LPR to PPD appears to be a useful marker to
measure the quality of immune response along with the
quantification of CD4+ (quantitative immune response)
for the selection of patients to discontinue HAART. How-
ever, further study is required to confirm this data.
We also found that IL-4 production in supernatant of
PBMC cultured with PPD and p24-Ag were strong predic-
tive markers of CD4+ falling below 350/µL. A previous
report showed that there are two types of lymphocytes
according to the cytokine secretion profile, and these pro-
files can be affected by HIV-infection [16]. Type-1 cells
produce high levels of IFN-γ, IL-2, and TNF-α, while Type-
2 cells preferentially secrete IL-4, IL-5 and IL-10 [16]. In
addition to being secreted by CD4+ T cells, it is now well
known that some of these cytokines are also secreted by
CD8+ and non-T cells. It is documented that the type-1 cel-
lular immune response is impaired during the course of
HIV infection [17]. In our study, the type-2 cytokine IL-4
was quantified and a higher production of IL-4 in PBMC
stimulated with PPD and p24-Ag was found. A possible
Kaplan-Meier for decreases in CD4+ T-cells (A) and rebound  of viral load (VL) (B) in HIV-infected patients after treatment  interruption Figure 1
Kaplan-Meier for decreases in CD4+ T-cells (A) and rebound 
of viral load (VL) (B) in HIV-infected patients after treatment 
interruption.
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explanation might be that an IL-4 increase produces a neg-
ative effect on IFN-γ production [16]. Thus, type-2 cells
may increase type-2 responses (increased production of
IL-4), B cells and/or suppress type-1 immune responses,
thus compromising host response to infectious agents
such as HIV [18].
The main limitation in our study is the small number of
patients. Thus, while LPR to PPD may have been predic-
tive of a certain outcome in this small number of patients
it is premature to conclude that it is clinically useful for
the selection of patients to discontinue HAART. We have
not shown it to be predictive in a multivariate analysis. It
is, in fact, quite possible that those individuals with lower
CD4+ nadirs are also those with poor CD4+ T cell function
and these assays simply identify the same individuals. Fur-
ther studies to look at this as an independent predictor
should be carried out with a larger number of patients. In
spite of this, we consider our data to be very interesting as
well as never having been previously described in non-
structured treatment interruption.
Conclusion
The conclusions of the study may be limited by the small
number of patients evaluated. However, the results sug-
gest that ART interruptions may be useful in a specific sub-
set of patients with a minimal CD4+ nadir and a good LPR
response. Most significantly, we have identified immuno-
logical markers that may help explain the dynamics of
CD4+ count decline after discontinuing ART and may help
identify patients that are most likely to benefit from a
potential interruption of therapy.
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